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Original Article
Dry eye (DE) syndrome is one of the most frequent dis-
eases encountered by ophthalmologists, and has a preva-
lence of 30% to 50% in the entire population [1-3] and a 
significant impact on daily life [4-6]. The etiology of DE 
syndrome has not been clearly established despite signifi-
cant research efforts; however, according to previous stud-
ies, DE is likely an immunological disorder [7]. Specifical-
ly, there are increased levels of inflammatory cytokines in 
induced DE, and these cytokines seem to play an import-
ant role in the inflammatory response of DE syndrome [7-
9]. In addition, clinical research on both humans and mice 
has confirmed the increased expression of cytokines such 
as IL-1a, IL-1b, IL-6, IL-8, IL-12, and TNF-α on the ocular 
surface of DEs [10-12]. 
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Purpose: Dry eye syndrome is commonly thought of as an inflammatory disease, and we have previously pre-
sented data showing the effectiveness of topical TNF-α blocker agents for the treatment of this condition. The 
purpose of this study was to investigate the effectiveness of the TNF-α blocking agent HL036337 compared 
to cyclosporine A for the treatment of dry eye induced inflammation in order to establish whether HL036337 
represents a more effective method for suppressing inflammation. The efficacy of HL036337 and cyclosporine 
A was determined using an experimental murine dry eye model.
Methods: The TNF-α blocker HL036337 is a modified form of TNF receptor I. Using dry eye induced C57BL/6 
mice (n = 45), corneal erosion was measured at day 4 and 7 after topical treatment with cyclosporine A or 
HL036337. To determine the effective treatment dose, 0.25, 0.5, 1, 2.5, and 5 mg/mL of HL036337 were topi-
cally administered twice per day to dry eye induced murine corneas for 1 week. 
Results: The optimal concentration of the TNF-α blocker HL036337 for treatment of dry eye induced corneal 
erosion was determined to be 1 mg/mL. Dry eye induced corneal erosion was improved after 1 week with top-
ically applied cyclosporine A and HL036337 at 1 mg/mL. 
Conclusions: HL036337 administered topically at 1 mg/mL effectively improved corneal erosion induced by dry 
eye. This finding may also suggest that inhibition of TNF-α can improve dry eye syndrome.
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Among the known inflammatory cytokines, TNF-α is 
understood to play multiple roles in inducing pro-inflam-
matory reactions and reciprocal stimulation [13]. TNF-α is 
involved in cellular transport and activation, pathogen re-
sistance, and regulation of immune/inflammatory respons-
es [14]. Accordingly, TNF-α has been utilized to develop a 
number of different drugs (e.g., TNF-α antagonist inflix-
imab, adalimumab, etanercept, etc.) for the treatment of 
diseases such as rheumatoid arthritis, Sjögren’s syndrome, 
and ankylosing spondylitis [14,15]. However, TNF-α block-
ers are not currently utilized as therapeutic agents for the 
treatment of DE syndrome. 
There have been numerous attempts to develop thera-
peutic agents against DE syndrome, but there remain many 
areas for improvement. Ji et al. [16] previously developed 
HL036337 by modifying the TNF-α receptor I, which we 
investigated as a new treatment for DE syndrome. The 
purpose of this study was to establish the maximal effec-
tive concentration of the TNF-α blocker agent HL036337 
via in vivo analysis of DE-induced inf lammation on the 
ocular surface tissue. In addition, we sought to determine 
whether HL036337 represents a more effective method to 
suppress inf lammation compared to cyclosporine A 
(Restasis; Allergan, Parsippany-Troy Hills, NJ, USA).
Materials and Methods 
Animals and dry eye induction
The study research protocol was approved by the Insti-
tutional Animal Care and Use Committee of Yonsei Uni-
versity College of Medicine. Six-week-old female C57BL/6 
mice (Charles River Laboratory, Wilmington, MA, USA) 
were used in accordance with the standards described in 
the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Vi-
sion Research. DE was induced by placing mice in a con-
trolled-environment chamber [17]. Five mice were allocat-
ed to each group (control and DE-induced). To achieve 
maximum ocular surface dryness, mice in the con-
trolled-environment chamber (relative humidity below 
20%) were given subcutaneous injections of 0.15 mL sco-
polamine hydrobromide (10 mg/mL; Sigma-Aldrich Chem-
ical, St. Louis, MO, USA) twice per day for the duration of 
the experiment. Each experiment was repeated three 
times, and we calculated average values of expression data 
from three biological replicates at each time point.
Treatment regimen and tissue preparations
Ten days after beginning the DE induction protocol, we 
confirmed the presence of grade 3 or higher corneal ero-
sions, after which mice were divided into a normal group 
(n = 5), DE-induced group (n = 5), HL036337 0.25 mg/mL 
treatment group (n = 5), HL036337 0.5 mg/mL treatment 
group (n = 5), HL036337 1 mg/mL treatment group (n = 5), 
HL036337 2.5 mg/mL treatment group (n = 5), HL036337 
5 mg/mL treatment group (n = 5), Restasis treatment 
group (n = 5), and vehicle (sodium acetate, pH 5.5) treat-
ment group (n = 5). DE-induced mice were treated by topi-
cal administration into the eyeballs at a volume of 10 μL 
twice per day. 
At the end of the study period, mice were euthanized in 
a CO2 chamber and corneas, lymph nodes (LNs), and lac-
rimal glands were collected. All tissues were stored at 
-70°C for quantitative reverse transcription (RT)-poly-
merase chain reaction (PCR).
  
Corneal erosion scoring 
Corneal erosion grading was performed before treat-
ment and again on treatment days 4 and 7. Briefly, at the 
end of treatment, 0.5% f luorescein (Alcon, Hünenberg, 
Switzerland) was applied to the lower conjunctival sac of 
the mice and after 3 minutes corneal fluorescein staining 
was examined with biomicroscopy. Punctate staining was 
evaluated using the Oxford Scheme grading system, which 
assigns a grade of 0 to 4. Corneal grading higher than 
grade 3 by the Oxford Scheme grading system was regard-
ed as proper induction of DE. 
Real-time polymerase chain reaction 
Corneas, LNs, and lacrimal glands were collected from 
each of the five mice per group and compared. RNA was 
isolated with the RNeasy Micro Kit (Qiagen, Hilden, Ger-
many) and reverse transcribed using the Superscript III Kit 
(Invitrogen, Carlsbad, CA, USA). Real-time PCR was per-
formed using TaqMan Universal Master Mix and the 
following preformulated primers: IFN-γ (Mm01168134_
m1; Applied Biosystems, Foster City, CA, USA), IL-6 
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(Mm00446190_m1), IL-1b (Mm00434228_m1), TNF-α 
(Mm004443260_g1), GAPDH (Mm99999915_g1). 
Statistics 
Statistical analysis was performed using SPSS ver. 21.0 
(IBM Co., Armonk, NY, USA), and all data were ex-
pressed as the mean ± standard deviation. Differences be-
tween groups were examined by Student’s t-test, Krus-
kal-Wallis test, or ANOVA where appropriate. Values of p 
less than 0.05 were considered statistically significant.
Results
Induction of the dry eye
DE was induced in the test group by subcutaneous injec-
tion of scopolamine hydrobromide 0.15 mL twice per day 
and harboring them in controlled-environment chamber at 
a humidity less than 20%. After inducing DE, 1-mL 0.5% 
fluorescein was applied into mouse conjunctival sac, and 
corneal fluorescein staining was examined using slit lamp 
microscopy. We observed erosion above grade 3 in most of 
the test group mice, confirming the effective induction of 
DE using the study protocol (Fig. 1A-1E). 
Treatment of HL036337 on dry eye-induced mice 
The TNF-α blocker agent HL036337 was administered 
topically on the corneas of DE-induced mice for 1 week 
and corneal changes were observed. Test groups were di-
vided into HL036337 0.25, 0.5, 1, 2.5, and 5 mg/mL treat-
ment groups. After 7 days of treatment, the corneal erosion 
grade was 3.7 ± 0.483 in the HL036337 0.25 mg/mL treat-
ment group, 3.0 ± 0.738 in the HL036337 0.5 mg/mL treat-
ment group, 1.7 ± 0.675 in the HL036337 1 mg/mL treat-
ment group, 2.7 ± 0.483 in the HL036337 2.5 mg/mL 
Fig. 1. Corneal erosion was measured followed by fluorescein cornea surface staining. Each group included six to eight corneas randomly 
selected from both eyes dry eye (DE) induction was performed for 10 days, after which corneal erosion in DE induced mice was mea-
sured and photographed. After 7 days of treatment with topical HL036337, corneal fluorescein staining was examined with a slit lamp 
biomicroscope and photos were taken. (A) Treatment with HL036337 0.25 mg/mL, (B) HL036337 0.5 mg/mL, (C) HL036337 1 mg/mL, (D) 
HL036337 2.5 mg/mL, and (E) HL036337 5 mg/mL. Representative photographs from each group are shown.
DE + HL036337 1 mg/mL DE + HL036337 1 mg/mL
Day 0 Day 7 Day 0 Day 7
DE + HL036337 0.25 mg/mL DE + HL036337 0.25 mg/mL DE + HL036337 2.5 mg/mL DE + HL036337 2.5 mg/mL
DE + HL036337 0.5 mg/mL DE + HL036337 0.5 mg/mL DE + HL036337 5 mg/mL DE + HL036337 5 mg/mL
A D
B
C
E
DE + HL036337 1 mg/mL DE + HL036337 1 mg/mL
Day 0 Day 7 Day 0 Day 7
DE + HL 36337 0.25 mg/mL DE + HL 36337 0.25 mg/mL DE + HL036337 2.5 mg/mL DE + HL036337 2.5 mg/mL
DE + HL 36337 0.5 mg/mL DE + HL 36337 0.5 mg/mL DE + HL036337 5 mg/mL DE + HL036337 5 mg/mL
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treatment group, and 2.8 ± 0.421 grade in the HL036337 5 
mg/mL treatment group. Decreased corneal erosion was 
most apparent in the HL036337 1 mg/mL treatment group 
(Table 1 and Fig. 2A-2C). 
Treatment of HL036337, vehicle and Restasis on dry 
eye-induced mice 
Three groups of DE-induced mice were treated topically 
with HL036337 1 mg/mL, vehicle, or Restasis and the ef-
fect of the treatments on corneal erosion were compared. 
The vehicle treatment group exhibited no significant dif-
ference compared to a mock-treated control group and ex-
hibited no improvement in corneal erosion. On the con-
trary, treatment with either HL036337 1 mg/mL or Restasis 
induced improvement in corneal erosion on the fourth and 
seventh day compared to the first day. Specifically, corneal 
erosion grades were below grade 2 in both treatment 
groups on day 7 (Table 1 and Fig. 3). 
Changes in cytokine levels in cornea and lymph node 
after HL036337 treatment 
Following DE induction for 10 days, topical eye drops 
were given to the mice groups and inflammatory cytokines 
in corneas and LNs were determined by quantitative RT-
PCR on day 7. Among the cytokines evaluated, expression 
of TNF-α, IL-6, IFN-γ, and IL-1b were decreased on the 
ocular surface and LNs of HL036337 treated mice in a 
dose dependent manner compared to the DE-induced 
group (p < 0.05) (Fig. 4). However, an increase in TNF-α, 
IFN-γ, and IL-1b expression was noted in the tissues of 
mice treated with 2.5 mg/mL HL036337. In addition, 
LYVE-1, a marker suggestive of lymphangiogenesis, was 
significantly decreased in corneas treated with HL036337 
compared to the DE-induced group (p < 0.05) (Fig. 4). 
Table 1. Corneal erosion grading after 7 days of topical eye drops treatment
Normal DE only DE + vehicle
DE + 
HL036337
0.25 mg/mL
DE +
HL036337 
0.5 mg/mL
DE +
HL036337
1 mg/mL
DE +
HL036337 
2.5 mg/mL
DE +
HL036337
5 mg/mL
DE+
Restasis
0.6 ± 0.516 4.0 ± 0 3.67 ± 0.516 3.7 ± 0.483 3.0 ± 0.738 1.7 ± 0.675 2.7 ± 0.483 2.8 ± 0.421 1.7 ± 0.823
Values are presented as mean ± standard deviation.
After 10 days of dry eye (DE) induction, topical eye drops were given to the mice and corneal fluorescein staining was exam ined with 
a slit lamp biomicroscope on treatment day 7. Groups were divided as follows: normal, DE induced, DE + vehicle, DE + HL036337 0.25 
mg/mL, DE + HL036337 0.5 mg/mL, DE + HL036337 1 mg/mL, DE + HL036337 2.5 mg/mL, DE + HL036337 5 mg/mL, and DE + 
Restasis. Punctate staining was evaluated in a masked fashion using the Oxford Scheme grading system, where a grade of 0 to 4 was 
given for each cornea. Each experiment was repeated three times (p < 0.05).
Fig. 2. After induction of dry eye (DE) for 10 days, topical eye drops were given to the mice groups and corneal fluorescein staining 
was examined with a slit lamp biomicroscope at day 0 , 4, and 7. The mice were then divided into groups as follows: DE induced, DE + 
HL036337 0.25 mg/mL (H 0.25), DE + HL036337 0.5 mg/mL (H 0.5), DE + HL036337 1 mg/mL (H 1.0), DE + HL036337 2.5 mg/mL (H 2.5), 
DE + HL036337 5 mg/mL (H 5.0), DE + Restasis, and DE + vehicle (D + V). Punctate staining was evaluated in a masked fashion using 
the Oxford Scheme grading system, where a grade of 0 to 4 was given for each cornea. Each experiment was repeated three times. Stu-
dent’s t-test, **p < 0.05. (A) Corneal erosion grading before topical eye drops treatment. (B) Corneal erosion grading after 4 days of topical 
eye drops treatment. (C) Corneal erosion grading after 7 days of topical eye drops treatment.
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Conversely, expression of the immunoregulatory cytokines 
TGF-β and IL-10 were increased in corneas treated with 
HL036337 (p < 0.05) (Fig. 4).
Discussion
Previously, Ji et al. [16] reported the development of 
HL036337 by modifying the TNF-α receptor I. Specifical-
ly, HL036337 is a synthesized peptide that resembles the 
TNF-α binding region of the TNF-α receptor I that was se-
lected from various candidate molecules generated by 
site-directed mutagenesis and use of substituted amino 
acid sequences of human TNFRSF1A, P19438 [16]. 
Although there are several TNF-α blockers that can bind 
TNF-α, none have been able to induce significant improve-
ment in DE [18-20]. Furthermore, in some cases, etanercept 
not only bound to and neutralized TNF-α, but also stabi-
lized TNF-α and extended its half-life [18-20]. This might 
be because temporary binding at a relatively low affinity is 
unable to sufficiently neutralize TNF-α activity. Impor-
tantly, the structural homology of HL036337 allows it to 
bind free TNF-α in ocular surface tissues, thereby neutral-
izing its activity [16]. Indeed, HL036337 binds tightly to 
TNF-α, and exhibits improved tissue penetration and high-
er tissue concentration in cornea, suggesting it may have 
improved effectiveness on the ocular surface [16]. 
In the present study, corneal erosion was reduced fol-
lowing administration of HL036337 to mice with induced 
DE. This study was also significant in that it established 
the optimal concentration of HL036337 for the treatment 
of DE. Specifically, we determined using a mouse in vivo 
study that the TNF-α blocker HL036337 at a concentration 
of 1 mg/mL is the most effective agent to reduce corneal 
erosion compared to other agents at different concentra-
tions. In addition, when compared using corneal erosion 
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Fig. 4. After 10 days of dry eye (DE) induction, topical eye drops 
were given to the mice groups and inf lammatory cytokines in 
corneas and lymph nodes (LNs) were determined by quantitative 
reverse transcription polymerase chain reaction at day 7. Groups 
were divided as follows: normal (N), DE + vehicle (D + V), DE 
+ HL036337 0.25 mg/mL (H 0.25), DE + HL036337 1 mg/mL (H 
1.0), and DE + HL036337 2.5 mg/mL (H 2.5). Six corneas and six 
to eight cervical LNs from five mice were included in each group. 
Each experiment was repeated three times. *p < 0.05.
Co
rne
al 
gra
din
g
Day
5
4
3
2
1
0
0 2 4 6 8
DE only
DE + HL036337 0.25 mg/mL
DE + HL036337 0.5 mg/mL
DE + HL036337 vehicle
DE + HL036337 1 mg/mL
DE + HL036337 2.5 mg/mL
DE + HL036337 5 mg/mL
DE Restasis 0.5 mg/mL
Fig. 3. Determination of clinical data. Corneal erosion treatment 
was evaluated for a week with topical application and compared 
to that of Restasis. Punctate staining was evaluated in a masked 
fashion using the Oxford Scheme grading system, where a grade 
of 0 to 4 was given for each cornea. Each experiment was repeat-
ed three times. DE = dry eye. p < 0.05. 
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staging, HL036337 1 mg/mL exhibited similar counter-ero-
sive effects as Restasis, which is currently available on the 
market [21].
HL036337 displayed a linear dosage-effect relation at 
concentrations up to 1 mg/mL, but not at concentrations 
above 1 mg/mL. As HL036337 is a binding peptide for 
TNF-α, it likely follows the dose-effect pattern of similar 
competitive inhibitors, which typically exhibits an effect 
reaching a saturation point. However, in our study, the ef-
fect of HL036337 was actually decreased at concentrations 
higher than 1 mg/mL rather than reaching the saturation 
point and forming plateau (Figs. 2 and 4). There are sever-
al potential explanations for this observation. First, it is 
known that TNF-α inhibitors may result in paradoxical in-
duction of autoimmunity, a situation in which the immune 
system produces antibodies against the inhibitor agent, 
leading to a loss of efficacy. Consistent with this possibili-
ty, several studies have reported that TNF inhibitors may 
result in production of neutralizing antibodies or auto-an-
tibodies, which in some cases led to allergic reactions and 
loss of drug-efficacy [22,23]. Thus, in the present study, 
higher concentrations of HL036337 might have produced 
neutralizing or autoantibodies. Second, as HL036337 in-
duced a decrease in the levels of free TNF-α, higher doses 
of HL036337 might have triggered homeostatic compensa-
tion of TNF-α production. Lastly, high dose HL036337 
might have stimulated production of inflammatory cyto-
kines. Further studies are needed to evaluate these possi-
bilities.  
Restasis, which consists of 0.05% cyclosporine A, is an 
immunosuppressive agent and recognized as an effective 
treatment in individuals with chronic DE patients [21]. 
When compared with measured corneal erosion stage lev-
el, 1 mg/mL HL036337 showed similar counter-erosive ef-
fects as Restasis. This result suggests that HL036337 could 
be used to regulate immune suppression reaction on the 
ocular surface. 
The mechanism action of cyclosporine A differs from 
HL036337. Specifically, cyclosporine A forms a heterodi-
meric complex inside T cell and acts on several targets that 
play central roles in signaling pathways, including the cal-
cineurin/NFAT pathway and JNK/p38 activation pathways 
[24]. As a result, cyclosporine A is able to inhibit T cells 
with high specificity. On the other hand, HL036337 binds 
directly to TNF-α outside of the cell. Based on the results 
of the present study, this mechanism may suggest that 
blockade of TNF-α is a new therapeutic target for the 
treatment of DE syndrome. Given the different mecha-
nisms of action of cyclosporine A and HL036337, future 
studies should investigate the combination of these two 
agents for the treatment of DE syndrome. 
In the present study, analysis of inflammatory cytokines 
in DE-induced mice using RT-PCR showed decreased lev-
els of TNF-α, IL-6, IFN-γ, IL-1b on the ocular surface and 
LN in the HL036337 treatment group. This result suggest-
ed that HL036337 can reduce inflammatory cytokines. On 
the other hand, expression of the immunoregulatory cyto-
kines TGF-β and IL-10 in corneas was increased by treat-
ment with HL036337. In addition, we observed reduced 
expression of LYVE-1 in the corneas of mice treated with 
HL036337, suggesting that the agent may inhibit transpor-
tation of inflammatory mediators from LN. These findings 
will require further investigation into the mechanisms of 
immune suppression by HL036337.
In conclusion, the present study describes the reduction 
of corneal erosion by HL036337 treatment on DE-induced 
mice and reveals the best concentration of HL036337. We 
provide evidence of improved ocular surface erosion and 
inhibition of some inf lammatory mediators by blocking 
TNF-α with HL036337. This result implies that proper in-
hibition of TNF-α can lead to improvement of DE disease. 
Therefore, HL036337 should be investigated further as a 
strategy to treat DE syndrome. Lastly, human trials will be 
needed to verify our in vivo results.
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